Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chewable vs Swallowable Mebendazole for Hookworm in Children
NCT03995680Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2019
- Primary completion
- Oct 2019
- Countries
- 1
- Sponsor
- Swiss Tropical and Public Health Institute
- Modality
- Small Molecules
- Drugs
- mebendazole
- Conditions
- hookworm infection
01
Overview
Phase 2, randomised, open-label trial of mebendazole in hookworm infection (2 arms), sponsored by Swiss Tropical and Public Health Institute. Primary endpoint: Geometric Mean Egg Reduction Rate. Started Jul 2019; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Chewable tablet of mebendazole
Experimental arm receiving chewable mebendazole
Swallowable tablet of mebendazole
Active comparator arm receiving swallowable mebendazole
03
Who it enrols
Children aged 3-12 years with hookworm infection (EPG > 100), excluding those who are pregnant, have severe anemia, or received anthelminthic treatment recently.
04
Endpoints
Primary
Geometric Mean Egg Reduction Rate
Secondary
Cure Rate
Geometric Mean Egg Reduction Rate
Arithmetic Mean Egg Reduction Rate
Beyond the preview
Go deeper on NCT03995680.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03995680.